104 related articles for article (PubMed ID: 32581137)
1. R-spondin2 Suppresses the Progression of Hepatocellular Carcinoma via MAPK Signaling Pathway.
Zheng C; Zhou F; Shi LL; Xu GF; Zhang B; Wang L; Zhuge Y; Zou XP; Wang Y
Mol Cancer Res; 2020 Oct; 18(10):1491-1499. PubMed ID: 32581137
[TBL] [Abstract][Full Text] [Related]
2. Long non-coding RNA LINC01503 promotes the progression of hepatocellular carcinoma via activating MAPK/ERK pathway.
Wang MR; Fang D; Di MP; Guan JL; Wang G; Liu L; Sheng JQ; Tian DA; Li PY
Int J Med Sci; 2020; 17(9):1224-1234. PubMed ID: 32547318
[No Abstract] [Full Text] [Related]
3. The 14-3-3σ protein promotes HCC anoikis resistance by inhibiting EGFR degradation and thereby activating the EGFR-dependent ERK1/2 signaling pathway.
Song J; Liu Y; Liu F; Zhang L; Li G; Yuan C; Yu C; Lu X; Liu Q; Chen X; Liang H; Ding Z; Zhang B
Theranostics; 2021; 11(3):996-1015. PubMed ID: 33391517
[TBL] [Abstract][Full Text] [Related]
4. HOXB7 promotes tumor progression via bFGF-induced activation of MAPK/ERK pathway and indicated poor prognosis in hepatocellular carcinoma.
Wang WM; Xu Y; Wang YH; Sun HX; Sun YF; He YF; Zhu QF; Hu B; Zhang X; Xia JL; Qiu SJ; Zhou J; Yang XR; Fan J
Oncotarget; 2017 Jul; 8(29):47121-47135. PubMed ID: 28454092
[TBL] [Abstract][Full Text] [Related]
5. Downregulation of castor zinc finger 1 predicts poor prognosis and facilitates hepatocellular carcinoma progression via MAPK/ERK signaling.
Wang JL; Yang MY; Xiao S; Sun B; Li YM; Yang LY
J Exp Clin Cancer Res; 2018 Mar; 37(1):45. PubMed ID: 29506567
[TBL] [Abstract][Full Text] [Related]
6. LINC00978 promotes hepatocellular carcinoma carcinogenesis partly via activating the MAPK/ERK pathway.
Zhang Q; Cheng S; Cao L; Yang J; Wang Y; Chen Y
Biosci Rep; 2020 Mar; 40(3):. PubMed ID: 32077915
[TBL] [Abstract][Full Text] [Related]
7. PNO1 regulates autophagy and apoptosis of hepatocellular carcinoma via the MAPK signaling pathway.
Han Z; Liu D; Chen L; He Y; Tian X; Qi L; Chen L; Luo Y; Chen Z; Hu X; Li G; Zhan L; Wang Y; Li Q; Chen P; Liu Z; Guo H
Cell Death Dis; 2021 May; 12(6):552. PubMed ID: 34050137
[TBL] [Abstract][Full Text] [Related]
8. The correlation of NLRC3 expression with the progression and prognosis of hepatocellular carcinoma.
Ma YY; Zhang GH; Li J; Wang SB; Hu ZM; Zhang CW; Li E
Hum Pathol; 2018 Dec; 82():273-281. PubMed ID: 30081150
[TBL] [Abstract][Full Text] [Related]
9. IFI44L is a novel tumor suppressor in human hepatocellular carcinoma affecting cancer stemness, metastasis, and drug resistance via regulating met/Src signaling pathway.
Huang WC; Tung SL; Chen YL; Chen PM; Chu PY
BMC Cancer; 2018 May; 18(1):609. PubMed ID: 29848298
[TBL] [Abstract][Full Text] [Related]
10. Upregulation of microRNA-140-3p inhibits epithelial-mesenchymal transition, invasion, and metastasis of hepatocellular carcinoma through inactivation of the MAPK signaling pathway by targeting GRN.
Zhang QY; Men CJ; Ding XW
J Cell Biochem; 2019 Sep; 120(9):14885-14898. PubMed ID: 31044454
[TBL] [Abstract][Full Text] [Related]
11. HSCs-derived COMP drives hepatocellular carcinoma progression by activating MEK/ERK and PI3K/AKT signaling pathways.
Li Q; Wang C; Wang Y; Sun L; Liu Z; Wang L; Song T; Yao Y; Liu Q; Tu K
J Exp Clin Cancer Res; 2018 Sep; 37(1):231. PubMed ID: 30231922
[TBL] [Abstract][Full Text] [Related]
12. CRISPR/Cas9-mediated knockout of NSD1 suppresses the hepatocellular carcinoma development via the NSD1/H3/Wnt10b signaling pathway.
Zhang S; Zhang F; Chen Q; Wan C; Xiong J; Xu J
J Exp Clin Cancer Res; 2019 Nov; 38(1):467. PubMed ID: 31727171
[TBL] [Abstract][Full Text] [Related]
13. Regulator of Calcineurin 1 Gene Isoform 4, Down-regulated in Hepatocellular Carcinoma, Prevents Proliferation, Migration, and Invasive Activity of Cancer Cells and Metastasis of Orthotopic Tumors by Inhibiting Nuclear Translocation of NFAT1.
Jin H; Wang C; Jin G; Ruan H; Gu D; Wei L; Wang H; Wang N; Arunachalam E; Zhang Y; Deng X; Yang C; Xiong Y; Feng H; Yao M; Fang J; Gu J; Cong W; Qin W
Gastroenterology; 2017 Sep; 153(3):799-811.e33. PubMed ID: 28583823
[TBL] [Abstract][Full Text] [Related]
14. LINC00707 promotes hepatocellular carcinoma progression through activating ERK/JNK/AKT pathway signaling pathway.
Wang J; Luo Z; Yao T; Li W; Pu J
J Cell Physiol; 2019 May; 234(5):6908-6916. PubMed ID: 30317590
[TBL] [Abstract][Full Text] [Related]
15. Long non‑coding RNA MKLN1‑AS aggravates hepatocellular carcinoma progression by functioning as a molecular sponge for miR‑654‑3p, thereby promoting hepatoma‑derived growth factor expression.
Gao W; Chen X; Chi W; Xue M
Int J Mol Med; 2020 Nov; 46(5):1743-1754. PubMed ID: 33000222
[TBL] [Abstract][Full Text] [Related]
16. Downregulation of Talin1 promotes hepatocellular carcinoma progression through activation of the ERK1/2 pathway.
Chen P; Lei L; Wang J; Zou X; Zhang D; Deng L; Wu D
Cancer Sci; 2017 Jun; 108(6):1157-1168. PubMed ID: 28375585
[TBL] [Abstract][Full Text] [Related]
17. Long noncoding RNA CCHE1 indicates a poor prognosis of hepatocellular carcinoma and promotes carcinogenesis via activation of the ERK/MAPK pathway.
Peng W; Fan H
Biomed Pharmacother; 2016 Oct; 83():450-455. PubMed ID: 27427851
[TBL] [Abstract][Full Text] [Related]
18. SYNJ2BP inhibits tumor growth and metastasis by activating DLL4 pathway in hepatocellular carcinoma.
Liu X; Zhou J; Zhou N; Zhu J; Feng Y; Miao X
J Exp Clin Cancer Res; 2016 Jul; 35(1):115. PubMed ID: 27440153
[TBL] [Abstract][Full Text] [Related]
19. Activation of PI3K/AKT is involved in TINAG-mediated promotion of proliferation, invasion and migration of hepatocellular carcinoma.
Zhang MH; Niu H; Li Z; Huo RT; Wang JM; Liu J
Cancer Biomark; 2018; 23(1):33-43. PubMed ID: 29991125
[TBL] [Abstract][Full Text] [Related]
20. MCM6 promotes metastasis of hepatocellular carcinoma via MEK/ERK pathway and serves as a novel serum biomarker for early recurrence.
Liu M; Hu Q; Tu M; Wang X; Yang Z; Yang G; Luo R
J Exp Clin Cancer Res; 2018 Jan; 37(1):10. PubMed ID: 29357919
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
